The effect of brain L-arginine on arterial pressure the arterial pressure, heart rate, and SNA measured 30 min after ICV injection of 10 mmol was investigated by injecting L- but which has not been demonstrated in animals. 5,6 This species difference may be attributable to the efitric oxide ( NO ) , a potent endotheliumderived vasodilator both in vivo and in vitro, 1,2 is synthesized from L-arginine in a reaction catalyzed by NO synthase. The intravenous administration of L-arginine reduces arte-fects of L-arginine on the central nervous system. Because the doses administered to animals are usually much higher than given to humans, the central effects of the L-arginine that reaches the brain may mask the
N rial pressure in humans, an effect that is especially marked in individuals with essential hypertension, 3, 4 but which has not been demonstrated in animals. 5, 6 This species difference may be attributable to the efitric oxide ( NO ) , a potent endotheliumderived vasodilator both in vivo and in vitro, 1,2 is synthesized from L-arginine in a reaction catalyzed by NO synthase. The intravenous administration of L-arginine reduces arte-fects of L-arginine on the central nervous system. Because the doses administered to animals are usually much higher than given to humans, the central effects of the L-arginine that reaches the brain may mask the no change in arterial pressure after intracerebroven-Kohden ) . The trachea was intubated with a cannula ( PE-240, Clay Adams; Becton-Dickinson ) for artificial tricular injection of L-arginine into pentobarbital-anesthetized rats. In an attempt to resolve this discrep-ventilation after skeletal muscle was paralyzed by injection of decamethonium bromide ( 0.2 mg / 100 g, intraancy, we have now further investigated the effects of intracerebroventricular injection of arginine in ure-venously ) ( Sigma, St. Louis, MO ) . thane-anesthetized rats.
Intracerebroventricular Injections A guide cannula ( 23-gauge stainless steel tube, 20 mm in length with METHODS a 30-gauge stylet ) was inserted into the right lateral Animal Preparation Twelve-week-old male Wistar ventricle. The stereotaxic coordinates were 1.6 mm right rats ( n Å 170, body mass 260 { 5 g ) were obtained lateral and 0.8 mm dorsoventral from the bregma, with from Oriental Bio-Service Laboratory ( Kyoto, Japan ) . the incisor bar set 3.3 mm below the interaural line. The experimental procedure was authorized by the Agents were injected intracerebroventricularly by inCommittee for Animal Research of Kyoto Prefectural serting an injection cannula ( 30-gauge stainless steel University of Medicine. Rats were anesthetized with needle ) connected to a 25-mL syringe into the guide urethane ( 120 mg / 100 g of body mass, intraperitone-cannula. Each injection ( 10 mL) was delivered manually ally ) ( Nakarai Tesque, Kyoto, Japan ) because it has lit-over a period of 10 sec. Methylene blue solution was tle effect on NO metabolism.
9 Catheters ( PE-50, Clay injected through the injection cannula at the end of each Adams; Becton-Dickinson, Parsippany, NJ ) were in-experiment to verify its correct placement in the right serted into the femoral artery for recording of arterial ventricle. pressure and into the femoral vein for injection of drugs. Arterial pressure was continuously recorded by Recording of Abdominal Sympathetic Nervous Activity The abdominal plexus was exposed via a left connecting the artery catheter to a small volume-displacement pressure transducer ( TP-200T; Nihon Koh-abdominal transverse incision, and the sympathetic nerve bundle emerging from the celiac ganglion was den, Tokyo, Japan ) . Heart rate ( beats /minute ) was automatically calculated by triggering of the femoral arte-placed over a bipolar electrode ( uninsulated tips 1 mm apart ) . The nerve spikes were amplified and recorded rial pulse pressure with a tachometer ( AT-601G; Nihon on a magnetic tape recorder ( TEAC, Tokyo, Japan ) to-immediately before use; the vehicle control comprised 5 mmol / L Na 2 CO 3 . OPC-21268 ( Otsuka, Osaka, gether with arterial pressure. At the end of each experiment, pentolinium tartrate ( Sigma ) was injected intra-Japan ) , a nonpeptide blocker of V 1 arginine vasopressin receptors, 13 was dissolved in 0.1 mol / L dimethyl sulfvenously to determine the noise level. Nerve activity was determined by counting the nerve firing rate, ex-oxide ( Sigma ) , which was also used as the vehicle control. cluding the noise obtained after tape playback. The activity was expressed as percent change from the baseExperimental Protocol Arterial pressure, heart rate, line. These methods are described in detail elsewhere. 10 and abdominal sympathetic nervous activity ( SNA ) Administered Agents L-or D-arginine ( Sigma ) and were recorded for ¢ 30 min after intracerebroventricuthe a 1 -adrenoceptor blocker bunazosin hydrochloride lar injection ( 0.1, 1, or 10 mmol) or intravenous injection ( Eisai, Tokyo, Japan ) were dissolved in saline ( 0.9% ( 1 or 10 mmol) of L-or D-arginine. IntracerebroventricuNaCl ) and the pH was adjusted to 7.5 with NaOH. The lar pretreatment with L-NMMA ( 1 mmol) 14 or CV-
12 was performed 30 or 15 min, respec-NMMA ) was synthesized as described previously 11 tively, before the intracerebroventricular injection of arand also dissolved in saline. Saline was used as the ginine, and intravenous pretreatment with OPC-21268 vehicle control for each of these agents. CV-11974, or (5 mg/kg) 13 or bunazosin hydrochloride ( 0.2 mg / 2-ethoxy-7-carboxyl-[ 2 -(1H-tetrazol-5-yl) biphenyl-4-kg ) 15 was performed 10 min before intracerebroventricyl ] methylbenzimidazole ( Takeda, Osaka, Japan ) , a ular injection of arginine. specific nonpeptide antagonist of the type 1 receptor for angiotensin II, 12 was dissolved in 25 mmol / L Statistical Analysis Data are expressed as means { SEM. Differences between experimental and control Na 2 CO 3 at a concentration of 10 mg /mL and diluted to a concentration of 2 mg /mL with physiological saline groups were evaluated by one-way analysis of variance / 2e15$$2162 04-03-97 13:00:45 eajhal EL: AJH
RESULTS

Cardiovascular and SNA Responses to the Intracerebroventricular Injection of L-or D-Arginine
The intracerebroventricular injection of 0.1 mmol of L-or Darginine had no effect on cardiovascular parameters or SNA. At a dose of 1 mmol, L-arginine reduced the arterial pressure from 20 to 30 min after the intracerebroventricular injection and inhibited SNA ( Figures 1 and  2A ) , whereas 1 mmol of D-arginine had no significant effect on arterial pressure, heart rate, or SNA ( Figure  2B ) . The intracerebroventricular injections of 10 mmol of L-arginine increased arterial pressure ( Figures 2A  and 3A ) , an effect that was apparent at 1 min, maximal at 2 min, and continued for 10 min. Heart rate was significantly decreased from 5 to 30 min, and SNA tended to increase at 1 to 2 min, but was significantly inhibited from 20 to 30 min after injection. At a dose of 10 mmol, D-arginine, induced a biphasic increase in arterial pressure, the first phase of which ( 0 to 5 min ) was similar in extent to that triggered by 10 mmol of Larginine and the second phase of which ( 5 to 30 min ) was accompanied by a marked stimulation of SNA and heart rate ( Figures 2B and 3B ) . The intravenous injection of either 1 or 10 mmol of L-or D-arginine had no significant effect on arterial pressure ( /1 to /3 mm Hg ) , heart rate ( 010 to 015 beats /min ) , or SNA ( /5% to /10%).
Effects of L-NMMA on Cardiovascular and SNA Responses to Intracerebroventricular Injection of L-or D-Arginine
At a dose of 1 mmol, L-NMMA had no significant effect on mean arterial pressure ( maximum changes: L-NMMA, /3 { 2 mm Hg; control, /2 { 2 mm Hg ) , heart rate ( maximum changes: L-NMMA, 012 { 5 beats /min; control, 08 { 7 beats /min ) , or for ú 1 h after intracerebroventricular injection. We administered L-or D-arginine 30 min after injection of 1 mmol L-NMMA. Because the peak pressor responses to 10 mmol of L-arginine or D-arginine ( first phase ) were pretreatment group, and both arterial pressure and apparent 2 min after intracerebroventricular injection SNA 30 min after L-arginine injection were significantly and both cardiovascular and SNA responses tended to higher in the pretreatment group than in the control stabilize by 30 min after the injection, we compared group. The bradycardia apparent from 5 to 30 min after changes in mean arterial pressure, heart rate, and SNA intracerebroventricular injection of 10 mmol L-arginine at these two time points between control and L-NMMA was also prevented by pretreatment with L-NMMA pretreatment groups. Pretreatment with L-NMMA ( Figure 4B ) . L-NMMA pretreatment had no effect on abolished the vasodepressor response and reduced the the changes in arterial pressure, heart rate, or SNA ininhibition of SNA induced by 1 mmol L-arginine 30 min duced by intracerebroventricular injection of 1 or 10 after intracerebroventricular injection ( Figure 4A ) . L-mmol D-arginine. NMMA pretreatment did not affect the peak pressor response apparent 2 min after intracerebroventricular Effects of OPC-21268, Bunazosin Hydrochloride, and CV-11974 on the Cardiovascular Responses to Intrainjection of 10 mmol of L-arginine. However, after the initial peak, arterial pressure gradually increased in the cerebroventricularInjectionof L-orD-Arginine Intra-/ 2e15$$2162 04-03-97 13:00:45 eajhal EL: AJH venous pretreatment with OPC-21268 did not affect the and D-arginine is that the former is a precursor for NO. Intracerebroventricular pretreatment with the NO synpressor response to intracerebroventricular injection of 10 mmol of L-or D-arginine ( Figure 5A ) . In contrast, thase inhibitor L-NMMA abolished the vasodepressor response and reduced the inhibition of SNA induced intravenous pretreatment with bunazosin hydrochloride inhibited the pressor response to intracerebroven-by intracerebroventricular injection of 1 mmol L-arginine. In addition, pretreatment with L-NMMA resulted tricular injection of L-arginine and both phases of the pressor responses to D-arginine ( Figure 5B ) . Intracere-in an increased arterial pressure and abolished the inhibition of SNA normally apparent 30 min after intracerebroventricular pretreatment with CV-11974 inhibited the pressor response to L-arginine and the first phase of broventricular injection of 10 mmol L-arginine. These results suggest that NO produced in the brain contrithe pressor response to D-arginine ( Figure 5C ) . Neither OPC-21268, nor bunazosin, nor CV-11974 affected the butes to the complex effects of intracerebroventricular injection of L-arginine. changes in heart rate induced by intracerebroventricular injection of 10 mmol L-or D-arginine.
The production of NO in the brain is thought to exert a vasodepressor action in rats at least in part by inhib-DISCUSSION iting peripheral SNA. 14 NO synthase is present in the cortex, cerebellum, hippocampus, hypothalamus, midThe intracerebroventricular injection of 1 mmol L-arginine induced a sustained vasodepressor response, brain, and medulla, including the nucleus tractus solitarius ( NTS ) and ventral medulla. 15, 16 Of these regions of whereas 10 mmol L-arginine elicited a transient pressor response; both doses of L-arginine induced a delayed rat brain, the NTS and ventral medulla are important regulators of arterial pressure and SNA. The NTS is rich inhibition of SNA. Unexpectedly, intracerebroventricular injection of 10 mmol D-arginine, which was used in N-methyl-D-aspartate ( NMDA ) -sensitive glutamate receptors, which have been shown to be coupled to NO as a control for L-arginine, elicited a biphasic pressor response, the first phase of which resembled the re-synthesis. 17 Microinjection of S-nitrosocysteine, which releases NO in vivo, into the rat NTS induces a dosesponse to 10 mmol L-arginine and the second long-lasting phase was accompanied by marked increases in dependent vasodepressor response and bradycardia. 18 In addition, NO inhibits the neuronal activity of the both heart rate and SNA. One difference between L-/ 2e15$$2162 04-03-97 13:00:45 eajhal EL: AJH 
